David A Tuveson

List of Publications by Year
in descending order

163 papers	61,138 citations	3731 89 h-index	5539 163 g-index
174 all docs	174 docs citations	174 times ranked	56216 citing authors

#	Article	IF	Citations
1	Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. New England Journal of Medicine, 2002, 347, 472-480.	27.0	4,018
2	Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science, 2009, 324, 1457-1461.	12.6	2,730
3	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 2003, 4, 437-450.	16.8	2,150
4	Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 2005, 7, 469-483.	16.8	2,137
5	A framework for advancing our understanding of cancer-associated fibroblasts. Nature Reviews Cancer, 2020, 20, 174-186.	28.4	2,012
6	Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor. New England Journal of Medicine, 2001, 344, 1052-1056.	27.0	1,926
7	Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature, 2011, 475, 106-109.	27.8	1,831
8	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 2012, 491, 399-405.	27.8	1,741
9	Analysis of lung tumor initiation and progression using conditional expression of oncogenic <i>K-ras</i>. Genes and Development, 2001, 15, 3243-3248.	5.9	1,663
10	Restoration of p53 function leads to tumour regression in vivo. Nature, 2007, 445, 661-665.	27.8	1,662
11	Organoid Models of Human and Mouse Ductal Pancreatic Cancer. Cell, 2015, 160, 324-338.	28.9	1,584
12	Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. Journal of Experimental Medicine, 2017, 214, 579-596.	8.5	1,582
13	Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with antiâ€“PD-L1 immunotherapy in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20212-20217.	7.1	1,482
14	Transcriptional Regulation by Nrf2. Antioxidants and Redox Signaling, 2018, 29, 1727-1745.	5.4	1,356
15	Pancreatic cancer. Nature Reviews Disease Primers, 2016, 2, 16022.	30.5	1,301
16	Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome. Cell, 2004, 119, 847-860.	28.9	1,140
17	Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature, 2011, 469, 539-542.	27.8	1,127
18	Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discovery, 2019, 9, 1102-1123.	9.4	1,120

#	Article	IF	Citations
19	The Pancreas Cancer Microenvironment. Clinical Cancer Research, 2012, 18, 4266-4276.	7.0	1,087
20	Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature, 2001, 410, 1111-1116.	27.8	1,060
21	Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Proteinâ€"Î±. Science, 2010, 330, 827-830.	12.6	952
22	Activated Kras and <i>Ink4a/Arf</i> deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes and Development, 2003, 17, 3112-3126.	5.9	912
23	Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy. Cell, 2014, 159, 80-93.	28.9	871
24	ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell, 2005, 8, 311-321.	16.8	866
25	Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut, 2013, 62, 112-120.	12.1	866
26	Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to Invasion. Cancer Research, 2007, 67, 9518-9527.	0.9	838
27	IL1-Induced JAK/STAT Signaling Is Antagonized by TGFÎ² to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancer Discovery, 2019, 9, 282-301.	9.4	778
28	Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell, 2004, 5, 375-387.	16.8	710
29	Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine, 2014, 211, 1503-1523.	8.5	683
30	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discovery, 2018, 8, 1112-1129.	9.4	676
31	Stromal biology and therapy in pancreatic cancer. Gut, 2011, 60, 861-868.	12.1	652
32	STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene, 2001, 20, 5054-5058.	5.9	643
33	Maximizing mouse cancer models. Nature Reviews Cancer, 2007, 7, 654-658.	28.4	617
34	InÂVivo Identification of Tumor- Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma. Cell, 2011, 147, 382-395.	28.9	602
35	Cancer modeling meets human organoid technology. Science, 2019, 364, 952-955.	12.6	577
36	Diversity and Biology of Cancer-Associated Fibroblasts. Physiological Reviews, 2021, 101, 147-176.	28.8	521

#	Article	IF	Citations
37	The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer. Cancer Research, 2005, 65, 10280-10288.	0.9	488
38	Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut, 2015, 64, 1476-1484.	12.1	444
39	Pathology of Genetically Engineered Mouse Models of Pancreatic Exocrine Cancer: Consensus Report and Recommendations. Cancer Research, 2006, 66, 95-106.	0.9	401
40	Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nature Genetics, 2020, 52, 231-240.	21.4	365
41	<i>nab</i>-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer. Cancer Discovery, 2012, 2, 260-269.	9.4	359
42	The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1. Cell, 2015, 162, 259-270.	28.9	359
43	Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell, 2017, 170, 875-888.e20.	28.9	339
44	Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Research, 2003, 63, 5198-202.	0.9	337
45	Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nature Cell Biology, 2016, 18, 549-560.	10.3	329
46	KrasG12D and Smad4/Dpc4 Haploinsufficiency Cooperate to Induce Mucinous Cystic Neoplasms and Invasive Adenocarcinoma of the Pancreas. Cancer Cell, 2007, 11, 229-243.	16.8	327
47	Retinoic Acidâ€"Induced Pancreatic Stellate Cell Quiescence Reduces Paracrine Wntâ€"Î²-Catenin Signaling to Slow Tumor Progression. Gastroenterology, 2011, 141, 1486-1497.e14.	1.3	316
48	Depletion of stromal cells expressing fibroblast activation protein-Î± from skeletal muscle and bone marrow results in cachexia and anemia. Journal of Experimental Medicine, 2013, 210, 1137-1151.	8.5	304
49	The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature, 2012, 486, 266-270.	27.8	297
50	Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors. Cancer Research, 2005, 65, 2412-2421.	0.9	296
51	NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer. Cell, 2016, 166, 963-976.	28.9	294
52	Somatic activation of oncogenic <i>Kras</i> in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 597-602.	7.1	279
53	Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic <i>BRAF</i> by the Kinase Inhibitor SB-590885. Cancer Research, 2006, 66, 11100-11105.	0.9	257
54	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discovery, 2018, 8, 1096-1111.	9.4	256

#	Article	IF	Citations
55	Stromal biology and therapy in pancreatic cancer: ready for clinical translation?. Gut, 2019, 68, 159-171.	12.1	246
56	Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19609-19618.	7.1	244
57	Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. Journal of Clinical Investigation, 2004, 113, 528-538.	8.2	231
58	ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature, 2020, 579, 130-135.	27.8	229
59	Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy. Cancer Discovery, 2019, 9, 852-871.	9.4	222
60	The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics. Clinical Cancer Research, 2006, 12, 5277-5287.	7.0	218
61	Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology, 2020, 159, 1129-1131.e3.	1.3	214
62	Crosstalk between the canonical NF-Î°B and Notch signaling pathways inhibits PparÎ³ expression and promotes pancreatic cancer progression in mice. Journal of Clinical Investigation, 2011, 121, 4685-4699.	8.2	213
63	Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors. Cancer Research, 2016, 76, 6851-6863.	0.9	209
64	CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12325-12330.	7.1	207
65	Roadmap for the Emerging Field of Cancer Neuroscience. Cell, 2020, 181, 219-222.	28.9	182
66	Modeling Pancreatic Cancer with Organoids. Trends in Cancer, 2016, 2, 176-190.	7.4	174
67	The Promise and Perils of Antioxidants for Cancer Patients. New England Journal of Medicine, 2014, 371, 177-178.	27.0	169
68	Understanding Metastasis in Pancreatic Cancer: A Call for New Clinical Approaches. Cell, 2012, 148, 21-23.	28.9	166
69	The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Science, 2019, 364, 1156-1162.	12.6	166
70	Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 2023-2037.	7.0	156
71	BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell, 2003, 4, 95-98.	16.8	154
72	SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. Journal of Clinical Investigation, 2011, 121, 4257-4267.	8.2	153

#	Article	IF	Citations
73	Requirement for Rac1 in a K-rasâ€“Induced Lung Cancer in the Mouse. Cancer Research, 2007, 67, 8089-8094.	0.9	148
74	Germline Brca2 Heterozygosity Promotes KrasG12D -Driven Carcinogenesis in a Murine Model of Familial Pancreatic Cancer. Cancer Cell, 2010, 18, 499-509.	16.8	147
75	TLR9 ligation in pancreatic stellate cells promotes tumorigenesis. Journal of Experimental Medicine, 2015, 212, 2077-2094.	8.5	142
76	A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel. Clinical Cancer Research, 2008, 14, 4836-4842.	7.0	136
77	<i>Mist1-KrasG12D</i> Knock-In Mice Develop Mixed Differentiation Metastatic Exocrine Pancreatic Carcinoma and Hepatocellular Carcinoma. Cancer Research, 2006, 66, 242-247.	0.9	132
78	C-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D. Cancer Discovery, 2011, 1, 128-136.	9.4	126
79	Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. Gastrointestinal Endoscopy, 2018, 87, 1474-1480.	1.0	126
80	SPARC independent drug delivery and antitumour effects of<i>nab</i>-paclitaxel in genetically engineered mice. Gut, 2014, 63, 974-983.	12.1	125
81	Modeling human lung cancer in mice: similarities and shortcomings. Oncogene, 1999, 18, 5318-5324.	5.9	121
82	BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E536-45.	7.1	121
83	Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes and Development, 2007, 21, 694-707.	5.9	120
84	Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening. SLAS Discovery, 2018, 23, 574-584.	2.7	119
85	Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer. Cancer Discovery, 2019, 9, 1268-1287.	9.4	119
86	The RON Receptor Tyrosine Kinase Mediates Oncogenic Phenotypes in Pancreatic Cancer Cells and Is Increasingly Expressed during Pancreatic Cancer Progression. Cancer Research, 2007, 67, 6075-6082.	0.9	108
87	Inflammation-Induced NFATc1â€“STAT3 Transcription Complex Promotes Pancreatic Cancer Initiation by <i>Kras</i>G12D. Cancer Discovery, 2014, 4, 688-701.	9.4	108
88	Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, 69, 1592-1597.	12.1	106
89	Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. Cancer Research, 2018, 78, 4253-4269.	0.9	105
90	Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism. Cell Reports, 2019, 29, 1287-1298.e6.	6.4	105

#	Article	IF	Citations
91	Cancer Cellâ€“Derived Matrisome Proteins Promote Metastasis in Pancreatic Ductal Adenocarcinoma. Cancer Research, 2020, 80, 1461-1474.	0.9	99
92	Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. Journal of Experimental Medicine, 2012, 209, 437-444.	8.5	92
93	Predictive in vivo animal models and translation to clinical trials. Drug Discovery Today, 2012, 17, 253-260.	6.4	92
94	A phase I trial of the Î³-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 2018, 118, 793-801.	6.4	90
95	Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. Cancer Discovery, 2020, 10, 1566-1589.	9.4	90
96	Ras redux: rethinking how and where Ras acts. Current Opinion in Genetics and Development, 2003, 13, 6-13.	3.3	80
97	Cancer lessons from mice to humans. Nature, 2011, 471, 316-317.	27.8	80
98	Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biology and Therapy, 2004, 3, 1058-1059.	3.4	78
99	Technologically advanced cancer modeling in mice. Current Opinion in Genetics and Development, 2002, 12, 105-110.	3.3	77
100	MRI with hyperpolarised [1-¹³C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model. Gut, 2016, 65, 465-475.	12.1	71
101	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. Clinical Cancer Research, 2016, 22, 1734-1743.	7.0	69
102	Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Gut, 2012, 61, 877-884.	12.1	68
103	Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Gut, 2013, 62, 1034-1043.	12.1	67
104	PanIN Neuroendocrine Cells Promote Tumorigenesis via Neuronal Cross-talk. Cancer Research, 2017, 77, 1868-1879.	0.9	67
105	SOAT1 promotes mevalonate pathway dependency in pancreatic cancer. Journal of Experimental Medicine, 2020, 217, .	8.5	65
106	Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade. Nature Communications, 2021, 12, 3414.	12.8	65
107	Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. Oncogene, 2019, 38, 5890-5904.	5.9	63
108	C-Raf Inhibits MAPK Activation and Transformation by B-RafV600E. Molecular Cell, 2009, 36, 477-486.	9.7	61

#	Article	IF	Citations
109	Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Annals of Surgery, 2020, 272, 427-435.	4.2	61
110	Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. ELife, 2020, 9, .	6.0	61
111	Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. ELife, 2020, 9, .	6.0	61
112	Mice Expressing a Mammary Glandâ€"Specific R270H Mutation in the p53 Tumor Suppressor Gene Mimic Human Breast Cancer Development. Cancer Research, 2005, 65, 8166-8173.	0.9	59
113	Organoid models for translational pancreatic cancer research. Current Opinion in Genetics and Development, 2019, 54, 7-11.	3.3	57
114	Modelling oncogenic Ras/Raf signalling in the mouse. Current Opinion in Genetics and Development, 2009, 19, 4-11.	3.3	55
115	Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nature Genetics, 2017, 49, 825-833.	21.4	55
116	Model organoids provide new research opportunities for ductal pancreatic cancer. Molecular and Cellular Oncology, 2016, 3, e1014757.	0.7	52
117	Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. Pancreatology, 2012, 12, 8-15.	1.1	49
118	A novel method for quantification of gemcitabine and its metabolites 2â€²,2â€²-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LCâ€"MS/MS: comparison with 19F NMR spectroscopy. Cancer Chemotherapy and Pharmacology, 2011, 68, 1243-1253.	2.3	48
119	The use of GEM models for experimental cancer therapeutics. DMM Disease Models and Mechanisms, 2008, 1, 83-86.	2.4	47
120	Bioactivation of Napabucasin Triggers Reactive Oxygen Speciesâ€"Mediated Cancer Cell Death. Clinical Cancer Research, 2019, 25, 7162-7174.	7.0	46
121	Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 6742-6755.	7.0	45
122	Organoid Models for Cancer Research. Annual Review of Cancer Biology, 2019, 3, 223-234.	4.5	44
123	SIRT1â€"NOX4 signaling axis regulates cancer cachexia. Journal of Experimental Medicine, 2020, 217, .	8.5	43
124	Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer. PLoS ONE, 2013, 8, e67330.	2.5	29
125	Deconstructing tumor heterogeneity: the stromal perspective. Oncotarget, 2020, 11, 3621-3632.	1.8	29
126	Signal transduction pathways in sarcoma as targets for therapeutic intervention. Current Opinion in Oncology, 2001, 13, 249-255.	2.4	28

#	Article	IF	Citations
127	Deciphering cancer fibroblasts. Journal of Experimental Medicine, 2018, 215, 2967-2968.	8.5	28
128	Deploying Mouse Models of Pancreatic Cancer for Chemoprevention Studies. Cancer Prevention Research, 2010, 3, 1382-1387.	1.5	27
129	Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Clinical Cancer Research, 2022, 28, 3296-3307.	7.0	27
130	Targeting oncogene dependence and resistance. Cancer Cell, 2003, 3, 414-417.	16.8	26
131	Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways. Blood, 2007, 109, 5238-5241.	1.4	26
132	Kâ€Rasâ€Driven Pancreatic Cancer Mouse Model for Anticancer Inhibitor Analyses. Methods in Enzymology, 2008, 439, 73-85.	1.0	26
133	Impaired JNK Signaling Cooperates with <i>KrasG12D</i> Expression to Accelerate Pancreatic Ductal Adenocarcinoma. Cancer Research, 2014, 74, 3344-3356.	0.9	26
134	Generation and Culture of Human Pancreatic Ductal Adenocarcinoma Organoids from Resected Tumor Specimens. Methods in Molecular Biology, 2019, 1882, 97-115.	0.9	26
135	Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial. Gut, 2022, 71, 879-888.	12.1	24
136	Dynamic changes during the treatment of pancreatic cancer. Oncotarget, 2018, 9, 14764-14790.	1.8	21
137	Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Oncotarget, 2016, 7, 33529-33541.	1.8	21
138	Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics. Cancer Research, 2022, 82, 1174-1192.	0.9	21
139	Securing the future of the clinician-scientist. Nature Cancer, 2020, 1, 139-141.	13.2	20
140	RhoC Interacts with Integrin Î±5Î²1 and Enhances Its Trafficking in Migrating Pancreatic Carcinoma Cells. PLoS ONE, 2013, 8, e81575.	2.5	20
141	Physiological Analysis of Oncogenic Kâ€Ras. Methods in Enzymology, 2006, 407, 676-690.	1.0	19
142	VAV1: A new target in pancreatic cancer?. Cancer Biology and Therapy, 2005, 4, 509-511.	3.4	18
143	Single-Pass vs 2-Pass Endoscopic Ultrasound-Guided Fine-NeedleÂBiopsy Sample Collection for Creation ofÂPancreatic Adenocarcinoma Organoids. Clinical Gastroenterology and Hepatology, 2021, 19, 845-847.	4.4	18
144	Untangling the genetics from the epigenetics in pancreatic cancer metastasis. Nature Genetics, 2017, 49, 323-324.	21.4	16

#	Article	IF	Citations
145	Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	16
146	Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Clinical Cancer Research, 2021, 27, 226-236.	7.0	15
147	Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 541-552.	3.3	14
148	Generation and Characterisation of a Pax8-CreERT2 Transgenic Line and a Slc22a6-CreERT2 Knock-In Line for Inducible and Specific Genetic Manipulation of Renal Tubular Epithelial Cells. PLoS ONE, 2016, 11, e0148055.	2.5	11
149	Challenges and Opportunities in Modeling Pancreatic Cancer. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 231-235.	1.1	8
150	Pancreatic cancer foiled by a switch of tumour subtype. Nature, 2018, 557, 500-501.	27.8	8
151	Generation and Culture of Tumor and Metastatic Organoids from Murine Models of Pancreatic Ductal Adenocarcinoma. Methods in Molecular Biology, 2019, 1882, 117-133.	0.9	8
152	Recapitulating human cancer in a mouse. Nature Biotechnology, 2013, 31, 392-395.	17.5	7
153	A FATal Combination: Fibroblast-Derived Lipids and Cancer-Derived Autotaxin Promote Pancreatic Cancer Growth. Cancer Discovery, 2019, 9, 578-580.	9.4	7
154	Impact of COVID-19 Pandemic on Cancer Research. Cancer Cell, 2020, 38, 591-593.	16.8	7
155	An shRNA silencing a nonâ€toxic transgene reduces nutrient consumption and increases production of adenoviral vectors in a novel packaging cell. Journal of Cellular Physiology, 2009, 219, 365-371.	4.1	6
156	Detecting and diagnosing ampullary neoplasms. Cancer Biology and Therapy, 2004, 3, 657-659.	3.4	5
157	Augmenting NF-Î°B in poor-risk CLL: A general paradigm for other cancers?. Journal of Experimental Medicine, 2015, 212, 830-831.	8.5	5
158	111 Successful Creation of Pancreatic Cancer Organoids By Means of Eus-Guided Fine-Needle Biopsy (EUS-FNB) for Personalized Cancer Treatment. Gastrointestinal Endoscopy, 2017, 85, AB50-AB51.	1.0	5
159	Soils and Seeds That Initiate Pancreatic Cancer Metastasis. Cancer Discovery, 2017, 7, 1067-1068.	9.4	5
160	Fighting the Sixth Decade of the Cancer War with Better Cancer Models. Cancer Discovery, 2021, 11, 801-804.	9.4	5
161	Kras in Organoids. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031575.	6.2	4
162	Immigration in science. Journal of Experimental Medicine, 2020, 217, .	8.5	2

#	Article	IF	Citations
163	Pancreatic cancer SLUGged. Journal of Experimental Medicine, 2020, 217, .	8.5	0